نبذة مختصرة : A 57-year old gentleman had presented a year back with inflammatory oligoarthritis and vasculitic neuropathy, diagnosed as unclassifiable vasculitis, initiated on oral corticosteroids and intravenous cyclophosphamide (monthly X 6). His disease stabilized and he had been maintained on azathioprine, which had to be stopped due to acute pancreatitis with subsequent pseudocyst formation, requiring percutaneous drainage suspecting infection. Within a week of pseudocyst drainage, he developed sudden onset pain in left upper limb, with absent left upper limb pulses, loss of motor function of left hand, myocardial ischemia, and extensive thrombosis of the left upper limb arteries. Neuropathy in the left upper limb was either vasculitic, or ischemic due to arterial thrombosis. However, multifocal thrombosis suggested an ongoing vasculitic flare. In view of possible infected pancreatic pseudocyst, intravenous methylprednisolone pulse was contra-indicated. Hence, he was offered intravenous immunoglobulin (IVIG) therapy, despite the risk of potentially worsening the prevalent prothrombotic state. On the second day of IVIG, he developed transiently tingling and weakness of right hand with vasculitic rashes, which subsequently resolved, reaffirming the suspicion of vasculitic flare. After completing IVIG therapy, the weakness in his left hand had markedly improved. His myocardial ischemia had also recovered, with a repeat echocardiography showing normalization of prior left ventricular hypokinesia. In the intervening period, the pseudocysts were drained, following which he was initiated on rituximab. This case highlights numerous challenges in the initial diagnosis, distinguishing vasculitic from ischemic neuropathy, and the management of vasculitic flare during infection.
(© 2020 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd.)
References: Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62:2569-2581. https://doi.org/10.1002/art.27584.
Scott DG, Bacon PA. Intravenous cyclophosphamide plus methylprednisolone in treatment of systemic rheumatoid vasculitis. Am J Med. 1984;76:377-384.
Lightfoot RW Jr, Michel BA, Bloch DA, et al. The American. College of Rheumatology 1990 criteria for the classification of polyarteritis nodosa. Arthritis Rheum. 1990; 33:1088-1093.
Leavitt RY, Fauci AS, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum. 1990;33:1101-1107.
Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65:1-11.
Haroon N, Agarwal V, Aggarwal A, Kumari N, Krishnani N, Misra R. Arthritis as presenting manifestation of pure neuritic leprosy - A rheumatologist's dilemma. Rheumatology. 2007;46:653-656. https://doi.org/10.1093/rheumatology/kel367.
Lamprecht P, Pipitone N, Gross WL. Unclassified vasculitis. Clin Exp Rheumatol. 2011;29:S81-85.
Wu X, Li G, Huang X, et al. Behçet's disease complicated with thrombosis: a report of 93 Chinese cases. Medicine. 2014;93:e263-e263. https://doi.org/10.1097/MD.0000000000000263.
Kang A, Antonelou M, Wong NL, et al. High incidence of arterial and venous thrombosis in antineutrophil cytoplasmic antibody-associated vasculitis. The Journal of Rheumatology. 2019;46:285-293.
Springer J, Villa-Forte A. Thrombosis in vasculitis. Curr Opin Rheumatol. 2013;25:19-25.
Parker B, Chattopadhyay C. A case of rheumatoid vasculitis involving the gastrointestinal tract in early disease. Rheumatology (Oxford). 2007;46:1737-1738.
Aggarwal R, Ringold S, Khanna D, et al. Distinctions Between Diagnostic and Classification Criteria? Arthritis Care Res. 2015;67:891-897.
June RR, Aggarwal R. The use and abuse of diagnostic/classification criteria. Best Pract Res Clin Rheumatol. 2014;28:921-934.
Emmi G, Silvestri E, Squatrito D, et al. Thrombosis in vasculitis: from pathogenesis to treatment. Thromb J. 2015;13:15.
Houben E, Penne EL, Voskuyl AE, et al. Cardiovascular events in anti-neutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis of observational studies. Rheumatology (Oxford). 2017; 57(3):555-562.
Suppiah R, Judge A, Batra R, et al. A model to predict cardiovascular events in patients with newly diagnosed Wegener’s granulomatosis and microscopic polyangiitis. Arthritis Care Res. 2011;63:588-596.
Bai YH, Li ZY, Chang DY, Chen M, Kallenberg CG, Zhao MH. The BVAS is an independent predictor of cardiovascular events and cardiovascular disease-related mortality in patients with ANCA-associated vasculitis: A study of 504 cases in a single Chinese center. Semin Arthritis Rheum. 2018;47:524-529.
Youssef J, Novosad SA, Winthrop KL. Infection Risk and Safety of Corticosteroid Use. Rheum Dis Clin North Am. 2016;42:157-x.
Gelfand EW. Intravenous immune globulin in autoimmune and inflammatory diseases. N Engl J Med. 2012;367:2015-2025.
Marie I, Maurey G, Herve F, Hellot MF, Levesque H. Intravenous immunoglobulin-associated arterial and venous thrombosis; report of a series and review of the literature. Br J Dermatol. 2006;155:714-721.
Shimizu T, Morita T, Kumanogoh A. The therapeutic efficacy of intravenous immunoglobulin in anti-neutrophilic cytoplasmic antibody-associated vasculitis: a meta-analysis. Rheumatology (Oxford). 2019. https://doi.org/10.1093/rheumatology/kez311.
Yates M, Watts RA, Bajema IM, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis. 2016;75:1583-1594.
Processing Request
No Comments.